Long-Term Experience of Tolvaptan
Kidney360 · 2025
DOI: 10.34067/kid.0000000934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney360, 2025. Verfasst von Pierre Antoine Brown und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Antidiuretic Hormone Receptor Antagonists, Chemical and Drug Induced Liver Injury, Polycystic Kidney, Autosomal Dominant, Benzazepines. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Otsuka Canada Pharmaceutical.
Abstract (Originalsprache)
In Canada, tolvaptan (JINARC) is approved for the treatment of adults with autosomal dominant polycystic kidney disease to slow the progression of kidney enlargement and kidney function decline. Safety data from the pivotal Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO 3:4) study suggested the potential for increased risk of liver injury with tolvaptan, which led to the establishment of the Canadian Hepatic Safety Monitoring and Distribution Programme in 2015. This review summarizes data regarding hepatic safety from clinical trials and presents data from established risk mitigation programs and real-world evidence. Data show that frequent liver function monitoring allows timely detection of drug-induced liver injury and prompt treatment interruption. To date, this approach has led to the absence of serious liver injury or liver failure in more than 2800 patients treated with tolvaptan in Canada over the past 10 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
- Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada.
- Otsuka Pharma GmbH, Frankfurt, Germany.
- Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Pierre Antoine Brown, Suzy Bubolic, Annick Laplante, Thomas Jaeger, Ahsan Alam
Förderung
- Otsuka Canada Pharmaceutical
Zitieren
APA
Brown, P. A., Bubolic, S., Laplante, A., Jaeger, T., & Alam, A. (2025). Long-Term Experience of Tolvaptan. Kidney360. https://doi.org/10.34067/kid.0000000934
Vancouver
Brown PA, Bubolic S, Laplante A, Jaeger T, Alam A. Long-Term Experience of Tolvaptan. Kidney360. 2025. doi:10.34067/kid.0000000934
BibTeX
@article{Brown2025,
author = {Brown, Pierre Antoine and Bubolic, Suzy and Laplante, Annick and Jaeger, Thomas and Alam, Ahsan},
title = {Long-Term Experience of Tolvaptan},
journal = {Kidney360},
year = {2025},
doi = {10.34067/kid.0000000934}
}
EUVIMED